GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE34931 Query DataSets for GSE34931
Status Public on Jan 09, 2012
Title Antibody profiling of smallpox vaccinees with/without a 'take' using custom vaccinia virus proteome microarrays
Platform organism Vaccinia virus WR
Sample organism Homo sapiens
Experiment type Protein profiling by protein array
Summary Successful vaccination against smallpox with conventional vaccinia virus is usually determined by the development of a vesicular skin lesion at the site of vaccinia inoculation, called a ‘take’. Although previous vaccination is known to be associated with attenuation of the take, the immunology that underlies a no-take in vaccinia-naïve individuals is not well understood. We hypothesized that antibody profiling of individuals before and after receiving vaccinia would reveal differences between takes and no-takes that may help better understand the phenomenon. Using vaccinia proteome microarrays and recombinant protein ELISAs we first examined the antibody response in vaccinia-naïve individuals that failed to take after receiving different doses of the replication competent smallpox vaccines, DryVax® and APSV. Most that received diluted vaccine failed to respond, whereas 4 other no-takes receiving diluted vaccine, and 4 receiving undiluted vaccine, mounted an antibody response. Interestingly, their antibody profiles were not significantly different from controls that did show a take. However, we did find elevated antibody titers in no-takes prior to receiving DryVax® that was significantly different from takes. Although the sample size studied was small, we conclude the failure to take in responders correlates with pre-existing immunity of unknown etiology that may attenuate the skin reaction in a way similar to previous smallpox vaccination.
Overall design Antibody profiling was peformed on sera from vaccinees receiving smallpox vaccines, either Wyeth DryVax or Aventis Pasteur Vaccine ('WetVax') in NIH-sponsored clinical trials. These samples comprise 23 vaccinia naïve no-takes, and 50 vaccinia naïve takes and 25 previoulsy vaccinated takes as controls. Samples from d0 (day of vaccination) and at the peak of the antibody repsonse (d28) were taken from each donor and probed in triplicate against the proteome arrays.
Contributor(s) Tan X, Chun S, Pablo J, Felgner P, Liang X, Davies H
Citation(s) 22258709, 25024392
Submission date Jan 09, 2012
Last update date Jan 02, 2015
Contact name David Huw Davies
Phone 949 824 7387
Organization name University of California Irvine
Department Medicine
Lab Division of Infectious Diseases
Street address Med Surge II
City Irvine
State/province CA
ZIP/Postal code 92697
Country USA
Platforms (1)
GPL15100 Antigen Discovery Vaccinia virus (strain WR) proteome microarray [batch VC11]
Samples (196)
GSM857577 1.d0
GSM857578 2.d0
GSM857579 3.d0
BioProject PRJNA150991

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE34931_raw_data.txt.gz 106.3 Kb (ftp)(http) TXT
Raw data are available on Series record
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap